RP2 and RPGR vectors for treating X-linked retinitis pigmentosa

ABSTRACT

Disclosed are adeno-associated virus (AAV) vectors comprising a nucleotide sequence encoding RP2 or RPGR-ORF15 and related pharmaceutical compositions. Also disclosed are methods of treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor number in a retina of a mammal, and increasing visual acuity of a mammal using the vectors and pharmaceutical compositions.

CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application is a divisional of U.S. patent application Ser.No. 15/556,746, filed Sep. 8, 2017, which is the U.S. National Stage ofPCT/US2016/022072, filed Mar. 11, 2016, which claims the benefit of U.S.Provisional Patent Application No. 62/131,661, filed Mar. 11, 2015, eachof which is incorporated by reference in its entirety herein.

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

Incorporated by reference in its entirety herein is a computer-readablenucleotide/amino acid sequence listing submitted concurrently herewithand identified as follows: One 77,721 Byte ASCII (Text) file named747471_ST25.txt, dated Feb. 21, 2020.

BACKGROUND OF THE INVENTION

X-linked retinitis pigmentosa (XLRP) is an X-linked, hereditary retinaldystrophy characterized by a progressive loss of photoreceptor cells,leading to vision impairment or blindness. XLRP may involve rodphotoreceptor death, followed by cone cell death. As a result, an XLRPpatient usually experiences an early onset of night-blindness, followedby a gradual but progressive loss of peripheral vision, and an eventualloss of central vision. There is currently no treatment for XLRP.Accordingly, there exists a need for compositions and methods fortreating XLRP.

BRIEF SUMMARY OF THE INVENTION

An embodiment of the invention provides an adeno-associated virus (AAV)vector comprising (a) a nucleotide sequence encoding RP2 or a functionalfragment thereof and (b) an AAV2 Inverted Terminal Repeat (ITR) or afunctional fragment thereof.

Another embodiment of the invention provides an AAV vector comprising anucleotide sequence encoding RPGR-ORF15 or a functional fragment orfunctional variant thereof, wherein (i) the vector further comprises aCMV/human β-globin intron and/or a human β-globin polyadenylationsignal; and (ii) the nucleotide sequence encoding RPGR-ORF15 or afunctional fragment or a functional variant thereof is optionally underthe transcriptional control of a rhodopsin kinase promoter.

Additional embodiments of the invention provide related pharmaceuticalcompositions and methods of making the AAV vector comprising anucleotide sequence encoding RPGR-ORF15 or a functional fragment orfunctional variant thereof.

Another embodiment of the invention provides a method of treating orpreventing X-linked retinitis pigmentosa (XLRP) in a mammal in needthereof, the method comprising administering to the mammal the inventivevector or pharmaceutical composition in an amount effective to treat orprevent XLRP in the mammal.

Still another embodiment of the invention provides a method ofincreasing photoreceptor number in a retina of a mammal, the methodcomprising administering to the mammal the inventive vector orpharmaceutical composition in an amount effective to increasephotoreceptor number in the retina of the mammal.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with an embodiment of the invention, it has beendiscovered that an AAV vector comprising a nucleotide sequence encodingRP2 or RPGR-ORF15 effectively preserved the function and viability ofphotoreceptors in mouse models of XLRP.

Approximately 15% of XLRP patients have a mutation in the RetinitisPigmentosa 2 (RP2) gene. The human RP2 gene has five exons and encodes aprotein of 350 amino acid residues. RP2 protein is a GTPase activatingprotein (GAP) for arginine adenosine-5′-diphosphoribosylation(ADP-ribosylation) factor-like 3 (ARL3), a microtubule-associated smallGTPase that localizes to the connecting cilium of photoreceptors. Anexample of a complementary DNA (cDNA) sequence encoding the human RP2protein is the nucleotide sequence of SEQ ID NO: 1. An example of aprotein sequence encoding the human RP2 protein is the amino acidsequence of SEQ ID NO: 2.

An embodiment of the invention provides an AAV vector comprising anucleic acid comprising (a) a nucleotide sequence encoding RP2 or afunctional fragment thereof and (b) an AAV2 ITR or a functional fragmentthereof. The nucleotide sequence encoding RP2 may be any suitablenucleotide sequence that encodes RP2 from any species. In a preferredembodiment, the RP2 is human RP2. In an embodiment of the invention, thenucleotide sequence encoding human RP2 comprises a nucleotide sequencethat encodes a human RP2 protein comprising the amino acid sequence ofSEQ ID NO: 2. In an embodiment of the invention, the nucleotide sequenceencoding human RP2 comprises the nucleotide sequence of SEQ ID NO: 1.

Approximately 75% of XLRP patients have a mutation in the RetinitisPigmentosa GTPase Regulator (RPGR) gene. Multiple RPGR transcripts havebeen detected in the retina. A majority of the disease-causing mutationshave been detected in a variant isoform RPGR-ORF15, which is expressedin the retina. RPGR-ORF15 protein interacts with centrosome-ciliaproteins and localizes to the connecting cilia in both rod and conephotoreceptors. An example of a cDNA sequence encoding the wild-typehuman RPGR-ORF15 protein is the nucleotide sequence of SEQ ID NO: 27. Anexample of a protein sequence encoding the wild-type human RPGR-ORF15protein is the amino acid sequence of SEQ ID NO: 4. An example of a cDNAsequence encoding a functional variant of the wild-type human RPGR-ORF15protein is the nucleotide sequence of SEQ ID NO: 3. An example of aprotein sequence encoding a functional variant of the wild-type humanRPGR-ORF15 protein is the amino acid sequence of SEQ ID NO: 25.

Another embodiment of the invention provides an AAV vector comprising anucleic acid comprising a nucleotide sequence encoding RPGR-ORF15 or afunctional fragment or functional variant thereof, wherein (i) thevector further comprises a CMV/human β-globin intron and/or a humanβ-globin polyadenylation signal; and (ii) the nucleotide sequenceencoding RPGR-ORF15 or a functional fragment or a functional variantthereof is optionally under the transcriptional control of a rhodopsinkinase promoter. In an embodiment of the invention, the AAV vectorcomprising a nucleic acid comprising a nucleotide sequence encodingRPGR-ORF15 or a functional fragment or functional variant thereof,wherein (i) the nucleotide sequence encoding human RPGR-ORF15 or afunctional fragment or functional variant thereof is under thetranscriptional control of a rhodopsin kinase promoter, and/or (ii) thevector further comprises a CMV/human β-globin intron and/or a humanβ-globin polyadenylation signal. The nucleotide sequence encodingwild-type RPGR-ORF15 may be any suitable nucleotide sequence thatencodes wild-type RPGR-ORF15 from any species. In a preferredembodiment, the RPGR-ORF15 is human RPGR-ORF15. In an embodiment of theinvention, the nucleotide sequence encoding wild-type human RPGR-ORF15comprises a nucleotide sequence that encodes a wild-type humanRPGR-ORF15 protein comprising the amino acid sequence of SEQ ID NO: 4.In an embodiment of the invention, the nucleotide sequence encodingwild-type human RPGR-ORF15 protein comprises the nucleotide sequence ofSEQ ID NO: 27. The nucleotide sequence encoding a functional variant ofa wild-type RPGR-ORF15 may be any suitable nucleotide sequence thatencodes a functional variant of the wild-type RPGR-ORF15. In a preferredembodiment, the functional variant of the RPGR-ORF15 is a functionalvariant of human RPGR-ORF15. In an embodiment of the invention, thenucleotide sequence encoding a functional variant of the wild-type humanRPGR-ORF15 comprises a nucleotide sequence that encodes a functionalvariant of the wild-type human RPGR-ORF15 protein comprising the aminoacid sequence of SEQ ID NO: 25. In an embodiment of the invention, thenucleotide sequence encoding a functional variant of the wild-type humanRPGR-ORF15 protein comprises the nucleotide sequence of SEQ ID NO: 3.Hereinafter, wild-type RPGR-ORF15 and functional variants of wild-typeRPGR-ORF15 will be collectively referred to as “RPGR-ORF15,” unlessspecified otherwise.

The AAV vector may be suitable for packaging into any AAV serotype orvariant thereof that is suitable for administration to ocular cells.Examples of suitable AAV serotypes may include, but are not limited to,AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and any variantthereof. Preferably, the AAV vector is packaged into serotype AAV8 orAAV9.

The AAV vector may be packaged in a capsid protein, or fragment thereof,of any of the AAV serotypes described herein. Preferably, the vector ispackaged in an AAV8 capsid. In an embodiment of the invention, the AAV8capsid comprises the amino acid sequence of SEQ ID NO: 5.

A suitable recombinant AAV may be generated by culturing a packagingcell which contains a nucleic acid sequence encoding an AAV serotypecapsid protein, or fragment thereof, as defined herein; a functional repgene; any of the inventive vectors described herein; and sufficienthelper functions to permit packaging of the inventive vector into theAAV capsid protein. The components required by the packaging cell topackage the inventive AAV vector in an AAV capsid may be provided to thehost cell in trans. Alternatively, any one or more of the requiredcomponents (e.g., inventive vector, rep sequences, capsid sequences,and/or helper functions) may be provided by a stable packaging cellwhich has been engineered to contain one or more of the requiredcomponents using methods known to those of skill in the art.

In an embodiment of the invention, the AAV vector is self-complementary.Self-complementary vectors may, advantageously, overcome therate-limiting step of second-strand DNA synthesis and confer earlieronset and stronger gene expression. Preferably, the AAV vectorcomprising a nucleotide sequence encoding RP2 is self-complementary. Inan embodiment, the vector comprises single-stranded DNA.

By “nucleic acid” as used herein includes “polynucleotide,”“oligonucleotide,” and “nucleic acid molecule,” and generally means apolymer of DNA or RNA, which can be single-stranded or double-stranded,synthesized or obtained (e.g., isolated and/or purified) from naturalsources, which can contain natural, non-natural or altered nucleotides,and which can contain a natural, non-natural or altered internucleotidelinkage, such as a phosphoroamidate linkage or a phosphorothioatelinkage, instead of the phosphodiester found between the nucleotides ofan unmodified oligonucleotide. It is generally preferred that thenucleic acid does not comprise any insertions, deletions, inversions,and/or substitutions. However, it may be suitable in some instances, asdiscussed herein, for the nucleic acid to comprise one or moreinsertions, deletions, inversions, and/or substitutions.

In an embodiment, the nucleic acids of the invention are recombinant. Asused herein, the term “recombinant” refers to (i) molecules that areconstructed outside living cells by joining natural or synthetic nucleicacid segments to nucleic acid molecules that can replicate in a livingcell, or (ii) molecules that result from the replication of thosedescribed in (i) above. For purposes herein, the replication can be invitro replication or in vivo replication.

The nucleic acids can be constructed based on chemical synthesis and/orenzymatic ligation reactions using procedures known in the art. See, forexample, Green et al. (eds.), Molecular Cloning, A Laboratory Manual,4th Edition, Cold Spring Harbor Laboratory Press, New York (2012). Forexample, a nucleic acid can be chemically synthesized using naturallyoccurring nucleotides or variously modified nucleotides designed toincrease the biological stability of the molecules or to increase thephysical stability of the duplex formed upon hybridization (e.g.,phosphorothioate derivatives and acridine substituted nucleotides).Examples of modified nucleotides that can be used to generate thenucleic acids include, but are not limited to, 5-fluorouracil,5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine,4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil,5-carboxymethylaminomethyl-2-thiouridine,5-carboxymethylaminomethyluracil, dihydrouracil,beta-D-galactosylqueosine, inosine, N⁶-isopentenyladenine,1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine,2-methylguanine, 3-methylcytosine, 5-methylcytosine, N⁶-substitutedadenine, 7-methylguanine, 5-methylaminomethyluracil,5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine,5′-methoxycarboxymethyluracil, 5-methoxyuracil,2-methylthio-N⁶-isopentenyladenine, uracil-5-oxyacetic acid (v),wybutoxosine, pseudouracil, queosine, 2-thiocytosine,5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,uracil-5-oxyacetic acid methylester, 3-(3-amino-3-N-2-carboxypropyl)uracil, and 2,6-diaminopurine. Alternatively, one or more of the nucleicacids of the invention can be purchased from companies, such asMacromolecular Resources (Fort Collins, Colo.) and Synthegen (Houston,Tex.).

In an embodiment of the invention, the vector is a recombinantexpression vector. For purposes herein, the term “recombinant expressionvector” means a genetically-modified oligonucleotide or polynucleotideconstruct that permits the expression of an mRNA, protein, polypeptide,or peptide by a host cell, when the construct comprises a nucleotidesequence encoding the mRNA, protein, polypeptide, or peptide, and thevector is contacted with the cell under conditions sufficient to havethe mRNA, protein, polypeptide, or peptide expressed within the cell.The vectors of the invention are not naturally-occurring as a whole.However, parts of the vectors can be naturally-occurring. The inventiverecombinant expression vectors can comprise any type of nucleotides,including, but not limited to DNA and RNA, which can be single-strandedor double-stranded, synthesized or obtained in part from naturalsources, and which can contain natural, non-natural or alterednucleotides. The recombinant expression vectors can comprisenaturally-occurring, non-naturally-occurring internucleotide linkages,or both types of linkages. Preferably, the non-naturally occurring oraltered nucleotides or internucleotide linkages do not hinder thetranscription or replication of the vector.

The recombinant expression vectors of the invention can be preparedusing standard recombinant DNA techniques described in, for example,Green et al., supra. Constructs of expression vectors, which arecircular or linear, can be prepared to contain a replication systemfunctional in a prokaryotic or eukaryotic host cell. Replication systemscan be derived, e.g., from ColEl, 2μ plasmid, λ, SV40, bovine papillomavirus, and the like.

The recombinant expression vector can include one or more marker genes,which allow for selection of transformed or transfected hosts. Markergenes include biocide resistance, e.g., resistance to antibiotics, heavymetals, etc., complementation in an auxotrophic host to provideprototrophy, and the like. Suitable marker genes for the inventiveexpression vectors include, for instance, neomycin/G418 resistancegenes, hygromycin resistance genes, histidinol resistance genes,tetracycline resistance genes, and ampicillin resistance genes.

The vector may further comprise regulatory sequences which are operablylinked to the nucleotide sequence encoding RP2 or RPGR-ORF15 in a mannerwhich permits one or more of the transcription, translation, andexpression of RP2 or RPGR-ORF15 in a cell transfected with the vector orinfected with a virus that comprises the vector. As used herein,“operably linked” sequences include both regulatory sequences that arecontiguous with the nucleotide sequence encoding RP2 or RPGR-ORF15 andregulatory sequences that act in trans or at a distance to control thenucleotide sequence encoding RP2 or RPGR-ORF15.

The regulatory sequences may include appropriate transcriptioninitiation, termination, promoter and enhancer sequences; RNA processingsignals such as splicing and polyadenylation (polyA) signal sequences;sequences that stabilize cytoplasmic mRNA; sequences that enhancetranslation efficiency (i.e., Kozak consensus sequence); sequences thatenhance protein stability; and when desired, sequences that enhancesecretion of the encoded product. PolyA signal sequences may besynthetic or may be derived from many suitable species, including, forexample, SV-40, human and bovine. Preferably, the vector comprises afull-length or truncated human beta (β)-globin polyA signal sequence. Inan embodiment of the invention, the human β-globin polyA signal sequencecomprises the nucleotide sequence of SEQ ID NO: 6 (full-length) or SEQID NO: 7 (truncated).

The regulatory sequences may also include an intron. Preferably, theintron is positioned between the promoter sequence and the nucleotidesequence encoding RP2 or RPGR-ORF15. Examples of suitable intronsequences include a cytomegalovirus (CMV)/human β-globin intron and anintron derived from SV-40 (referred to as SD-SA). Preferably, the intronis a CMV/human β-globin intron. In an embodiment of the invention, theCMV/human β-globin intron comprises the nucleotide sequence of SEQ IDNO: 8 or 9.

The regulatory sequences may also include a promoter. The promoter maybe any promoter suitable for expressing RP2 or RPGR-ORF15 in a targetcell, e.g., an ocular cell. The promoter may be inducible orconstitutive. In an embodiment of the invention, the promoter issuitable for expressing RP2 or RPGR-ORF15 in a particular ocular celltype. In this regard, the promoter may be cell-specific. For example,the promoter may be specific for expression in any one or more of ocularcells, retinal pigment epithelium (RPE) cells, photoreceptor cells, inrods, or in cones. Examples of suitable promoters include, but are notlimited to, the human G-protein-coupled receptor protein kinase 1 (GRK1)promoter (also referred to as the human rhodopsin kinase promoter), thehuman interphotoreceptor retinoid-binding protein proximal (IRBP)promoter, the native promoter for RP2 or RPGR-ORF15, the RPGR proximalpromoter, the rod opsin promoter, the red-green opsin promoter, the blueopsin promoter, the cGMP-β-phosphodiesterase promoter, the mouse opsinpromoter, the rhodopsin promoter, the alpha-subunit of cone transducin,beta phosphodiesterase (PDE) promoter, the retinitis pigmentosa (RP1)promoter, the NXNL2/NXNL1 promoter, the RPE65 promoter, the retinaldegeneration slow/peripherin 2 (Rds/perphZ) promoter, the VMD2 promoter,and functional fragments of any of the foregoing. Preferably, thenucleotide sequence encoding RP2 or RPGR-ORF15 is under thetranscriptional control of the GRK1 promoter (also referred to as humanrhodopsin kinase promoter). In an embodiment of the invention, the humanrhodopsin kinase promoter comprises the nucleotide sequence of SEQ IDNO: 10.

In an embodiment of the invention, the vector comprises an ITR or afunctional fragment thereof. Preferably, the vector comprises a 5′ and a3′ AAV ITR. The ITRs may be of any suitable AAV serotype, including anyof the AAV serotypes described herein. The ITRs may be readily isolatedusing techniques known in the art and may be isolated or obtained frompublic or commercial sources (e.g., the American Type CultureCollection, Manassas, Va.). Alternatively, the ITR sequences may beobtained through synthetic or other suitable means by reference topublished sequences. Preferably, the vector comprises a 5′ and a 3′ AAV2ITR. In an embodiment of the invention, the vector comprises a truncated5′ AAV2 ITR. In an embodiment of the invention, the vector comprises a5′ AAV2 ITR comprising the nucleotide sequence of SEQ ID NO: 11 and a 3′AAV2 ITR comprising the nucleotide sequence of SEQ ID NO: 12. In anotherembodiment of the invention, the vector comprises a truncated 5′ AAV2ITR comprising the nucleotide sequence of SEQ ID NO: 13 and a 3′ AAV2ITR comprising the nucleotide sequence of SEQ ID NO: 12.

Included in the scope of the invention are vectors comprising functionalfragments of any of the nucleotide sequences described herein thatencode functional fragments of the proteins described herein. The term“functional fragment,” when used in reference to a RP2 or RPGR-ORF15protein, refers to any part or portion of the protein, which part orportion retains the biological activity of the protein of which it is apart (the parent protein). Functional protein fragments encompass, forexample, those parts of a protein that retain the ability to recognizetreat or prevent XLRP, increase photoreceptor number, decrease retinaldetachment in a mammal, increase the electrical response of aphotoreceptor in a mammal, increase protein expression in a retina of amammal, localize protein to rod outer segments in a retina of a mammal,or increase visual acuity in a mammal, to a similar extent, the sameextent, or to a higher extent, as the parent protein. For example, afunctional fragment of a nucleotide sequence encoding RPGR-ORF15 may bea cDNA encoding RPGR-ORF15 but shortened by 654 base pairs (bp) in therepetitive region, which has been shown to reconstitute RPGR function inmice (Hong et al., Invest. Ophthalmol. Vis. Sci., 46(2): 435-441(2005)).

The term “functional fragment” when used in reference to a polyA signalsequence or an ITR, refers to any part or portion of the nucleotidesequence, which part or portion retains the biological activity of thenucleotide sequence of which it is a part (the parent nucleotidesequence). Functional protein fragments encompass, for example, thoseparts of a polyA signal sequence that retain the ability to berecognized by a RNA cleavage complex or those parts of an ITR thatretain the ability to allow for replication to a similar extent, thesame extent, or to a higher extent, as the parent nucleotide sequence.In reference to the parent nucleotide sequence or protein, thefunctional fragment can comprise, for instance, about 10%, 25%, 30%,50%, 68%, 80%, 90%, 95%, or more, of the parent nucleotide sequence orprotein.

Included in the scope of the invention are vectors encoding functionalvariants of the RP2 and RPGR-ORF15 proteins described herein. The term“functional variant,” as used herein, refers to a protein havingsubstantial or significant sequence identity or similarity to a parentprotein, which functional variant retains the biological activity of theprotein of which it is a variant. Functional variants encompass, forexample, those variants of the RP2 or RPGR-ORF15 proteins describedherein (the parent protein) that retain the ability to treat or preventXLRP, increase photoreceptor number, decrease retinal detachment in amammal, increase the electrical response of a photoreceptor in a mammal,increase protein expression in a retina of a mammal, localize protein torod outer segments in a retina of a mammal, and/or increase visualacuity in a mammal to a similar extent, the same extent, or to a higherextent, as the parent RP2 or RPGR-ORF15 protein. In reference to theparent RP2 or RPGR-ORF15 protein, the functional variant can, forinstance, be at least about 30%, about 50%, about 75%, about 80%, about85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%,about 96%, about 97%, about 98%, about 99% or more identical in aminoacid sequence to the parent RP2 or RPGR-ORF15 protein.

A functional variant can, for example, comprise the amino acid sequenceof the parent RP2 or RPGR-ORF15 protein with at least one conservativeamino acid substitution. Alternatively or additionally, the functionalvariants can comprise the amino acid sequence of the parent RP2 orRPGR-ORF15 protein with at least one non-conservative amino acidsubstitution. In this case, it is preferable for the non-conservativeamino acid substitution to not interfere with or inhibit the biologicalactivity of the functional variant. The non-conservative amino acidsubstitution may enhance the biological activity of the functionalvariant, such that the biological activity of the functional variant isincreased as compared to the parent RP2 or RPGR-ORF15 protein.

Amino acid substitutions of the parent RP2 or RPGR-ORF15 protein arepreferably conservative amino acid substitutions. Conservative aminoacid substitutions are known in the art, and include amino acidsubstitutions in which one amino acid having certain physical and/orchemical properties is exchanged for another amino acid that has thesame or similar chemical or physical properties. For instance, theconservative amino acid substitution can be an acidic/negatively chargedpolar amino acid substituted for another acidic/negatively charged polaramino acid (e.g., Asp or Glu), an amino acid with a nonpolar side chainsubstituted for another amino acid with a nonpolar side chain (e.g.,Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Cys, Val, etc.), abasic/positively charged polar amino acid substituted for anotherbasic/positively charged polar amino acid (e.g. Lys, His, Arg, etc.), anuncharged amino acid with a polar side chain substituted for anotheruncharged amino acid with a polar side chain (e.g., Asn, Gln, Ser, Thr,Tyr, etc.), an amino acid with a beta-branched side-chain substitutedfor another amino acid with a beta-branched side-chain (e.g., Ile, Thr,and Val), an amino acid with an aromatic side-chain substituted foranother amino acid with an aromatic side chain (e.g., His, Phe, Trp, andTyr), etc.

The RP2 or RPGR-ORF15 protein or functional variant can consistessentially of the specified amino acid sequence or sequences describedherein, such that other components, e.g., other amino acids, do notmaterially change the biological activity of the RP2 or RPGR-ORF15protein or functional variant.

In an embodiment of the invention, the RP2 vector comprises a nucleotidesequence comprising the components set forth in Table 1. In this regard,the full-length RP2 vector may comprise the nucleotide sequence of SEQID NO: 14.

TABLE 1 RP2 vector (SEQ ID NO: 14) Nucleotide Position of SEQ SEQ ID IDNO: 14 NO: Component  1-106 13 5′ AAV2 ITR (truncated) 137-432 10 humanrhodopsin kinase promoter 446-730 9 CMV/human β-globin intron  759-18111 human RP2 cDNA 1817-1930 7 human β-g1obin polyadenylation signal(truncated) 1943-2087 12 3′ AAV2 ITR

In an embodiment of the invention, the vector encoding a functionalvariant of wild-type human RPGR-ORF15 comprises a nucleotide sequencecomprising the components set forth in Table 2. In this regard, thefull-length vector encoding a functional variant of wild-type humanRPGR-ORF15 (SEQ ID NO: 25) may comprise the nucleotide sequence of SEQID NO: 15.

TABLE 2 Functional Variant of Wild-Type Human RPGR-ORF15 vector (SEQ IDNO: 15) Nucleotide Position of SEQ ID SEQ ID NO: 15 NO: Element  1-13011 5′ AAV2 Inverted Terminal Repeat (ITR) 140-434 10 human rhodopsinkinase promoter 449-668 8 cytomegalovirus (CMV)/human β-g1obin intron 686-4144 3 functional variant of wild-type human RPGR-ORF15 cDNA4194-4403 6 human β-g1obin polyadenylation signal 4417-4561 12 3′ AAV2ITR

In an embodiment of the invention, the vector encoding wild-type humanRPGR-ORF15 comprises a nucleotide sequence comprising the components setforth in Table 3. In this regard, the full-length vector encodingwild-type human RPGR-ORF15 (SEQ ID NO: 4) may comprise the nucleotidesequence of SEQ ID NO: 26.

TABLE 3 Wild-Type Human RPGR-ORF15 vector (SEQ ID NO: 26) NucleotidePosition of SEQ ID SEQ ID NO: 26 NO: Element  1-130 11 5′ AAV2 InvertedTerminal Repeat (ITR) 140-434 10 human rhodopsin kinase promoter 449-6688 cytomegalovirus (CMV)/human β-globin intron  686-4144 27 wild-typehuman RPGR-ORF15 cDNA 4194-4403 6 human β-g1obin polyadenylation signal4417-4561 12 3′ AAV2 ITR

An embodiment of the invention provides an AAV vector comprising anucleic acid comprising a nucleotide sequence encoding mouse RPGR-ORF15or a functional fragment thereof. The nucleotide sequence encoding mouseRPGR-ORF15 may comprise a nucleotide sequence encoding a mouseRPGR-ORF15 protein comprising the amino acid sequence of SEQ ID NO: 23.The vector may further comprise regulatory sequences which are operablylinked to the nucleotide sequence encoding mouse RPGR-ORF15 as describedherein with respect to other aspects of the invention. In an embodimentof the invention, the AAV vector comprising a nucleic acid comprising anucleotide sequence encoding mouse RPGR-ORF15 comprises the nucleotidesequence of SEQ ID NO: 24.

In an embodiment of the invention, the vector may also comprise anucleotide sequence that is about 70% or more, e.g., about 80% or more,about 90% or more, about 91% or more, about 92% or more, about 93% ormore, about 94% or more, about 95% or more, about 96% or more, about 97%or more, about 98% or more, or about 99% or more identical to any of thenucleotide sequences described herein.

An embodiment of the invention provides a method of making any of theAAV vectors comprising a nucleotide sequence encoding RPGR-ORF15 or afunctional fragment or functional variant thereof described herein. Themethod may comprise amplifying the purine-rich region of RPGR-ORF15 or afunctional variant thereof using genomic DNA as a template. Amplifyingmay be carried out by any suitable method known in the art. For example,the amplifying may be carried out by PCR. The method may compriseligating the purine-rich region to a nucleotide sequence encoding exons1 to 14 of RPGR-ORF15 or a functional variant thereof. Ligating may becarried out by any suitable method known in the art (see, e.g., Greenesupra). The method may further comprise propagating the vector in aXL10-gold bacterial strain.

The inventive vectors can be formulated into a composition, such as apharmaceutical composition. In this regard, the invention provides apharmaceutical composition comprising any of the vectors describedherein, and a pharmaceutically acceptable carrier. Any suitable carriercan be used within the context of the invention, and such carriers arewell known in the art. The choice of carrier will be determined, inpart, by the particular site to which the composition is to beadministered (e.g., ocular cells, RPE cells, photoreceptor cells, rods,and cones) and the particular method used to administer the composition.The pharmaceutical composition can optionally be sterile or sterile withthe exception of the one or more adeno-associated viral vectors.

Suitable formulations for the pharmaceutical composition include aqueousand non-aqueous solutions, isotonic sterile solutions, which can containanti-oxidants, buffers, and bacteriostats, and aqueous and non-aqueoussterile suspensions that can include suspending agents, solubilizers,thickening agents, stabilizers, and preservatives. The formulations canbe presented in unit-dose or multi-dose sealed containers, such asampules and vials, and can be stored in a freeze-dried (lyophilized)condition requiring only the addition of the sterile liquid carrier, forexample, water, immediately prior to use. Extemporaneous solutions andsuspensions can be prepared from sterile powders, granules, and tablets.Preferably, the carrier is a buffered saline solution. More preferably,the pharmaceutical composition for use in the inventive method isformulated to protect the adeno-associated viral vectors from damageprior to administration. For example, the pharmaceutical composition canbe formulated to reduce loss of the adeno-associated viral vectors ondevices used to prepare, store, or administer the expression vector,such as glassware, syringes, or needles. The pharmaceutical compositioncan be formulated to decrease the light sensitivity and/or temperaturesensitivity of the adeno-associated viral vectors. To this end, thepharmaceutical composition preferably comprises a pharmaceuticallyacceptable liquid carrier, such as, for example, those described above,and a stabilizing agent selected from the group consisting ofpolysorbate 80, L-arginine, polyvinylpyrrolidone, trehalose, andcombinations thereof. Use of such a composition may extend the shelflife of the vector, facilitate administration, and increase theefficiency of the inventive method. A pharmaceutical composition alsocan be formulated to enhance transduction efficiency of theadeno-associated viral vector. In addition, one of ordinary skill in theart will appreciate that the pharmaceutical composition can compriseother therapeutic or biologically-active agents. For example, factorsthat control inflammation, such as ibuprofen or steroids, can be part ofthe pharmaceutical composition to reduce swelling and inflammationassociated with in vivo administration of the adeno-associated viralvectors. Antibiotics, i.e., microbicides and fungicides, can be presentto treat existing infection and/or reduce the risk of future infection,such as infection associated with gene transfer procedures.

It is contemplated that the inventive vectors and pharmaceuticalcompositions (hereinafter referred to collectively as “inventive AAVvector materials”) can be used in methods of treating or preventingXLRP. In this regard, an embodiment of the invention provides a methodof treating or preventing XLRP in a mammal comprising administering tothe mammal any of the inventive AAV vector materials described herein,in an amount effective to treat or prevent the XLRP in the mammal.

The terms “treat” and “prevent” as well as words stemming therefrom, asused herein, do not necessarily imply 100% or complete treatment orprevention. Rather, there are varying degrees of treatment or preventionof which one of ordinary skill in the art recognizes as having apotential benefit or therapeutic effect. In this respect, the inventivemethods can provide any amount or any level of treatment or preventionof XLRP in a mammal. Furthermore, the treatment or prevention providedby the inventive method can include treatment or prevention of one ormore conditions, symptoms, or signs of XLRP. In some cases, theinventive methods may cure XLRP. Also, for purposes herein, “prevention”can encompass delaying the onset of XLRP, or a symptom, sign, orcondition thereof.

For example, the inventive methods may ameliorate, correct or stop theprogression of any one or more of a loss of photoreceptor structureand/or function; thinning or thickening of the outer nuclear layer(ONL); thinning or thickening of the outer plexiform layer (OPL);shortening of the rod and cone inner segments; retraction of bipolarcell dendrites; thinning or thickening of the inner retinal layersincluding inner nuclear layer, inner plexiform layer, ganglion celllayer and nerve fiber layer; opsin mislocalization; overexpression ofneurofilaments; retinal detachment in a mammal, decrease in theelectrical response of a photoreceptor in a mammal, loss ofelectroretinography (ERG) function; loss of visual acuity and contrastsensitivity; loss of visually guided behavior; decreased peripheralvision, decreased central vision, decreased night vision, loss ofcontrast sensitivity, and loss of color perception.

The inventive methods, vectors and pharmaceutical compositions mayprovide any one or more advantages. For example, the inventive methods,vectors and pharmaceutical compositions may improve the health orquality of the retina and may reduce or prevent vision impairment.Accordingly, the inventive methods, vectors and pharmaceuticalcompositions may, advantageously, improve a patient's ability to carryout vision-guided activities such as, for example, driving an automobileand living independently.

It is contemplated that the inventive vectors and pharmaceuticalcompositions can be used in methods of increasing photoreceptor numberin a retina of a mammal. In this regard, an embodiment of the inventionprovides a method of increasing photoreceptor number in a retina of amammal, the method comprising administering to the mammal any of theinventive AAV vector materials described herein, in an amount effectiveto increase photoreceptor number in the retina of the mammal.

The inventive vectors and pharmaceutical compositions may also be usefulfor increasing visual acuity in a mammal. In this regard, an embodimentof the invention provides a method of increasing visual acuity of amammal, the method comprising administering to the mammal any of theinventive AAV vector materials described herein, in an amount effectiveto increase visual acuity in the mammal.

The inventive vectors and pharmaceutical compositions may also be usefulfor decreasing retinal detachments in a mammal. In this regard, anembodiment of the invention provides a method of decreasing retinaldetachment in a mammal, the method comprising administering to themammal any of the inventive AAV vector materials described herein, in anamount effective to decrease retinal detachment in the mammal.

The inventive vectors and pharmaceutical compositions may also be usefulfor increasing the electrical response of a photoreceptor in a mammal.In this regard, an embodiment of the invention provides a method ofincreasing the electrical response of a photoreceptor in a mammal, themethod comprising administering to the mammal any of the inventive AAVvector materials described herein, in an amount effective to increasethe electrical response of a photoreceptor in the mammal. Thephotoreceptor may include, for example, one or both of rods and cones.The electrical response of a photoreceptor may be measured by anysuitable method known in the art such as, for example,electroretinography (ERG).

Another embodiment of the invention provides a method of increasingexpression of a protein in a retina of a mammal. The method may compriseadministering to the mammal any of the inventive AAV RP2 vectorsdescribed herein or a pharmaceutical composition comprising the vectorin an amount effective to increase expression of the protein in theretina of the mammal. In an embodiment of the invention, the protein isRP2, cone opsin, or cone PDE6.

Another embodiment of the invention provides a method of increasingexpression of a protein in a retina of a mammal, the method comprisingadministering to the mammal any of the inventive RPGR vectors describedherein or a pharmaceutical composition comprising the vector in anamount effective to increase expression of a protein in the retina ofthe mammal. In an embodiment of the invention, the protein is RPGR.

Another embodiment of the invention provides a method of localizing aprotein to the rod outer segments in the retina of a mammal. The methodmay comprise administering to the mammal any of the inventive RPGRvectors described herein or a pharmaceutical composition comprising thevector in an amount effective to localize the protein to the rod outersegments in the retina of the mammal. In an embodiment of the invention,the protein is rhodopsin or PDE6.

The inventive methods may comprise administering the AAV vector materialto the eye of the mammal, for example, intraocularly, subretinally, orintravitreally. Preferably, the AAV vector material is administeredsubretinally.

For purposes of the invention, the amount or dose of the inventive AAVvector material administered should be sufficient to effect a desiredresponse, e.g., a therapeutic or prophylactic response, in the mammalover a reasonable time frame. For example, the dose of the inventive AAVvector material should be sufficient to treat or prevent XLRP, increasephotoreceptor number, and/or increase visual acuity, in a period of fromabout 2 hours or longer, e.g., 12 to 24 or more hours, from the time ofadministration. In certain embodiments, the time period could be evenlonger. The dose will be determined by the efficacy of the particularinventive AAV vector material and the condition of the mammal (e.g.,human), as well as the body weight of the mammal (e.g., human) to betreated.

Many assays for determining an administered dose are known in the art.An administered dose may be determined in vitro (e.g., cell cultures) orin vivo (e.g., animal studies). For example, an administered dose may bedetermined by determining the IC₅₀ (the dose that achieves ahalf-maximal inhibition of signs of disease), LD₅₀ (the dose lethal to50% of the population), the ED₅₀ (the dose therapeutically effective in50% of the population), and the therapeutic index in cell culture,animal studies, or combinations thereof. The therapeutic index is theratio of LD₅₀ to ED₅₀ (i.e., LD₅₀/ED₅₀).

The dose of the inventive AAV vector material also may be determined bythe existence, nature, and extent of any adverse side effects that mightaccompany the administration of a particular inventive AAV vectormaterial. Typically, the attending physician will decide the dosage ofthe inventive AAV vector material with which to treat each individualpatient, taking into consideration a variety of factors, such as age,body weight, general health, diet, sex, inventive AAV vector material tobe administered, route of administration, and the severity of thecondition being treated. By way of example and not intending to limitthe invention, the dose of the inventive AAV vector material can beabout 1×10⁸ to about 2.5×10⁸ vector genomes (vg) per eye, about 1×10⁸ toabout 1×10⁹ vector genomes (vg) per eye, or about 1×10⁶ to about 1×10¹³vg per eye. In an embodiment of the invention, the dose of the inventiveRP2 vector is about 5×10⁶ to about 5×10¹², about 5×10⁶ to about 5×10⁸,or about 5×10⁷ to about 5×10⁸ vector genomes (vg) per eye. In anotherembodiment of the invention, the dose of the inventive RPGR-ORF15 vectoris about 5×10⁶ to about 5×10¹², about 1×10⁸ to about 5×10⁹ vg per eye,preferably about 5×10⁸ to about 2×10⁹ vg per eye. A dose of theinventive RPGR-ORF15 vector of about 1×10⁹ vg per eye is especiallypreferred. In another embodiment of the invention, the dose of theinventive mouse RPGR-ORF15 vector is about 1×10⁸ to about 5×10⁸ vg pereye, preferably about 3×10⁸ vg per eye.

As used herein, the term “mammal” refers to any mammal, including, butnot limited to, mammals of the order Rodentia, such as mice andhamsters, and mammals of the order Logomorpha, such as rabbits. It ispreferred that the mammals are from the order Carnivora, includingFelines (cats) and Canines (dogs). It is more preferred that the mammalsare from the order Artiodactyla, including Bovines (cows) and Swines(pigs) or of the order Perssodactyla, including Equines (horses). It ismost preferred that the mammals are of the order Primates, Ceboids, orSimoids (monkeys) or of the order Anthropoids (humans and apes). Anespecially preferred mammal is the human.

The following examples further illustrate the invention but, of course,should not be construed as in any way limiting its scope.

Examples 1-6

The following materials and methods were employed for Examples 1-6:

Mouse Line and Husbandry

Rpgr-knockout (KO) mice were maintained in National Institutes of Health(NIH) animal care facilities in controlled ambient illumination on a 12hour (h) light/12 h dark cycle. Studies conform to Association forResearch in Vision and Ophthalmology (ARVO) statement for the Use ofAnimals in Ophthalmic and Vision Research. Animal protocols wereapproved by National Eye Institute (NEI) Animal Care and Use Committee.

AAV Vector Construction and Production

The purine-rich region of the mouse or human RPGR-ORF15 exon waspolymerase chain reaction (PCR)-amplified from the genomic DNA of a maleC57 mouse or a healthy adult male donor, respectively. The 3′ DNA ofexon ORF15 including a Sap I restriction enzyme site and the adjacentpurine-rich region was PCR amplified from genomic DNA of a healthy adultmale donor. Sequences of the primers are as follows:

mRpgr forward (F): SEQ ID NO: 16;

mRpgr reverse (R): SEQ ID NO: 17;

hRPGR F: SEQ ID NO: 18; and

hRPGR R: SEQ ID NO: 19.

PCR was performed with PRIMESTAR HS DNA Polymerase (ClontechLaboratories, Inc., Mountain View, Calif.). The PCR conditions were 94°C. for 1 minute followed by 30 cycles at 98° C. for 10 seconds and 72°C. for 80 seconds; followed by 7 minutes of extension at 72° C. and holdat 4° C. The PCR products were verified by sequencing (Sequetech Inc.,Redwood City, Calif.) and ligated to the synthetic upstream exons togenerate a full length human or mouse RPGR-ORF15 cDNA. Exons 1 to 14 and5′ part of exon ORF15 with the Sap I site was synthesized. ThePCR-amplified and the synthesized DNA fragments were digested with Sap Irespectively, and then ligated to assemble the full-length humanRPGR-ORF15 cDNA (SEQ ID NO: 3). Mouse full-length Rpgr-ORF15 cDNA wasgenerated using the same strategy.

AAV type 2 inverted terminal repeats (ITRs) (SEQ ID NOs: 11 and 12) wereused in the AAV vector construction. The RPGR-ORF15 expression cassettesincluded a human rhodopsin kinase promoter (SEQ ID NO: 10) (Khani etal., Invest. Ophthalmol. Vis. Sci., 48: 3954-3961 (2007)), a chimericCMV/human β-globin intron (SEQ ID NO: 8), the human (SEQ ID NO: 3) ormouse RPGR-ORF15 cDNA and a human β-globin polyadenylation site (SEQ IDNO: 6). The vector plasmids were propagated in a XL10-gold bacterialstrain (Agilent Technologies, Inc., Santa Clara, Calif.).

AAV vectors were produced by triple-plasmid transfection to HEK293cells, as described in (Grimm et al., Blood, 102: 2412-2419 (2003)). Thehuman RPGR-ORF15 AAV construct was packaged into AAV8, while the mouseRpgr-ORF15 construct was packaged into both AAV8 and AAV9. The vectorswere purified by polyethylene glycol precipitation followed by cesiumchloride density gradient fractionation, as described in Grimm, supra.Purified vectors were formulated in 10 mM Tris-HCl, 180 mM NaCl, pH 7.4,quantified by real-time PCR using linearized plasmid standards, andstored at −80° C. until use. Integrity of the vectors was examined eachtime after purification by amplifying the purine-rich region of theRPGR-ORF15 cDNA.

Subretinal Injections

AAV vectors were injected subretinally, as described in Sun et al., GeneTher., 17: 117-131 (2010) but with some modifications. Briefly, micewere anesthetized by intra-peritoneal injection of ketamine (80 mg/kg)and xylazine (8 mg/kg). Pupils were dilated with topical atropine (1%)and tropicamide (0.5%). Surgery was performed under an ophthalmicsurgical microscope. A small incision was made through the corneaadjacent to the limbus using 18-gauge needle. A 33-gauge blunt needlefitted to a Hamilton syringe was inserted through the incision whileavoiding the lens and pushed through the retina. All injections weremade subretinally in a location within the nasal quadrant of the retina.Each animal received 1 μl of AAV vector at the concentration of 1×10¹¹to 1×10¹³ vector genomes per ml. Treatment vectors were given in theright eye, and control vehicle was injected in the fellow eye.Visualization during injection was aided by addition of fluorescein (100mg/ml AK-FLUOR, Alcon, Fort Worth, Tex.) to the vector suspensions at0.1% by volume. The dose efficacy studies were carried out on more than100 Rpgr-knockout (KO) mice.

Immunoblot Analysis

Mouse retinas were homogenized in radioimmunoprecipitation assay (RIPA)lysis buffer containing 1× proteinase inhibitor by brief sonication. Thetissue debris was removed by a brief centrifugation. Retinal protein wasseparated on sodium dodecyl sulfate (SDS)-polyacrylamide gel byelectrophoresis and transferred to nitrocellulose membranes. Afterpre-adsorption with 5% nonfat dry milk for 1 h at room temperature, themembrane blots were incubated overnight at 4° C. with the primaryantibody. The blots were then washed with Tris buffered saline with theTWEEN 20 detergent (TBST: 137 mM Sodium Chloride, 20 mM Tris, 0.1%Tween-20, pH 7.6), incubated for 1 h at room temperature with thesecondary antibody-horseradish peroxidase conjugated goat anti-rabbit oranti-mouse IgG (Jackson Immunoresearch, West Grove, Pa.), and developedby SUPERSIGNAL West Pico Chemiluminescent (Thermo Fisher ScientificInc., Rockford, Ill.). The primary antibodies used in this study were:rabbit anti-mouse RPGR-ORF15 antibody C100 and rabbit anti-human RPGRantibody 643, which recognize the C-terminal of the mouse RPGR-ORF15 anda common region of human RPGR-ORF15 and RPGR¹⁻¹⁹ isoforms, respectively.Mouse monoclonal anti-β-actin antibody (Sigma) was used for loadingcontrols.

Tissue Processing, Immunofluorescence and Morphometric Analysis

After euthanasia, mouse eyes were harvested. A blue dye was used to markthe orientation of the eye before enucleation to ensure thatimmunostaining was performed on equivalent areas on vector-treated andvehicle-treated eyes. For fixation, eyes were immediately placed in 4%paraformaldehyde for 1 h. The fixed tissues were soaked in 30%sucrose/PBS overnight, quickly frozen and sectioned at 10-μm thicknessusing cryostat. An alternative protocol was used to detect RPGRlocalization to the connecting cilia, as described in Hong et al.,Invest. Ophthalmol. Vis. Sci., 44: 2413-2421 (2003). Briefly, eyes wereembedded in optimal cutting temperature compound (OCT) without fixationand quick-frozen in liquid nitrogen. Cryosections were cut at 10 μm andcollected on pretreated glass slides (Superfrost Plus; FisherScientific, Pittsburgh, Pa.). Sections were stored at −80° C. and usedwithin 2 to 3 days. Just before use, sections were fixed on slides for 2min with 1% formaldehyde in phosphate-buffered saline (PBS) at pH 7.0.If sections were stored for longer than 1 week, an additional treatmentwas performed in 0.1% 2-mercaptomethanol (in PBS) for 5 minutes (min),followed by 1% formaldehyde fixation for 5 min. Sections were thenwashed once in PBS and carried through to immunofluorescence staining.

For immunofluorescence staining, the cryosections were pre-adsorbed in5% goat serum in PBS containing 0.1% Triton X-100 (PBST) for 1 h, andthen incubated overnight at 4° C. in primary antibody diluted in 5% goatserum, as described in Hong et al., Invest. Ophthalmol. Vis. Sci., 44:2413-2421 (2003). Sections were washed three times in PBST and incubatedwith fluorochrome-conjugated secondary antibodies and 0.2 μg/ml DAPI(4′,6-diamidino-2-phenylindole) for 1 h. Sections were washed again andmounted in FLUOROMOUNT-G mounting medium (SouthernBiotech, Birmingham,Ala.). Images were captured using a fluorescence microscope AXIO IMAGERZ1 or a confocal scanning microscope LSM700 (Zeiss, Germany).

The primary antibodies included the poly-clonal rabbit anti-humanRPGR-ORF15 antibody 636 and rabbit anti-mouse RPGR-ORF15 antibody S1(Hong et al., Invest. Ophthalmol. Vis. Sci., 43: 3373-3382 (2002)),which recognize the common region of RPGR-ORF15 and RPGR¹⁻¹⁹ isoforms inhuman and mouse, respectively. Other primary antibodies used in thisstudy include monoclonal antibody for rhodopsin (1D4, Santa CruzBiotechnology, Dallas, Tex.) and M-cone opsin (Millipore, Billerica,Mass.). Secondary antibodies included goat anti-rabbit and anti-mouseantibodies conjugated with ALEXA FLUOR 555 and 568 dyes (LifeTechnologies, Grand Island, N.Y.).

For morphometric analyses of outer nuclear layer (ONL) thickness,measurements were made along the vertical meridian at four locations toeach side of the optic nerve head separated by 500 μm each. Measurementsbegan at about 500 μm from the optic nerve head itself.

Electroretinogram (ERG)

Mice were dark-adapted overnight. Anesthesia and pupil dilation wereconducted as described above. A computer-based system (ESPION E2electroretinography system, Diagnosys LLC, Lowell, Mass.) was used forERG recordings in response to flashes produced with light-emitting diode(LED) or Xenon bulbs. Corneal ERGs were recorded from both eyes usinggold wire loop electrodes with a drop of 2.5% hypromellose ophthalmicdemulcent solution. A gold wire loop placed in the mouth was used asreference, and a ground electrode was on the tail. The ERG protocolconsisted of recording dark-adapted ERGs using brief flashes of −2 to +3log sc cd·s·m⁻²/flash. Responses were computer averaged and recorded at3 to 60 second (s) intervals depending upon the stimulus intensity.Light-adapted ERGs were recorded after 2 min of adaptation to a white 32cd·m⁻² rod-suppressing background. ERGs were recorded for stimulusintensities of −0.52 to +2 log sc cd·s·m⁻².

Optical Coherence Tomography (OCT)

OCT volume scan images were acquired with a spectral domain (SD) OCTsystem (SPECTRALIS system, Heidelberg Engineering, Carlsbad, Calif.).Mice were anesthetized and pupils were dilated as described above. Theoptic nerve head was centered within ˜1.0 mm diameter field of view.Retinal thickness maps were generated by Heidelberg Eye Explorersoftware.

Statistical Analysis

Two-tailed paired t-test was used to compare outcomes in vector-treatedversus vehicle-treated eyes. GRAPHPAD Prism 6 software (GraphPadSoftware, La Jolla, Calif.) was used for statistical analysis.

Example 1

This example demonstrates the generation of mouse and human RPGR-ORF15AAV vectors.

AAV vectors carrying either a mouse or a human RPGR-ORF15 expressioncassette were constructed. Previous efforts to obtain a full-lengthRPGR-ORF15 cDNA using reverse transcription PCR had not been successfuldue to the purine-rich region of the terminal ORF15 exon. To overcomethis problem, regular PCR was conducted using genomic DNA as a templateto amplify the purine-rich region, and then the purine-rich region wasligated to a synthetic DNA fragment encoding the upstream exons. Thisstrategy was adopted for obtaining both mouse and human RPGR-ORF15 cDNA.Sequencing of the complete cDNA was performed to validate the products.A human rhodopsin kinase (RK) promoter (SEQ ID NO: 10), which shows rodand cone cell specificity (Khani et al., Invest. Ophthalmol. Vis. Sci.,48: 3954-3961 (2007)), was used to drive RPGR-ORF15 expression. Thesetwo vectors were packaged into AAV type 8 and are hereafter referred toas AAV8-mRpgr and AAV8-hRPGR, respectively. The mouse RPGR-ORF15 vectorwas also packaged into AAV type 9 (hereafter referred to AAV9-mRpgr), aserotype that transduces cones of non-human primate efficiently(Vandenberghe et al., PLoS Pne, 8: e53463 (2013)).

The vector plasmids containing the purine-rich region of RPGR-ORF15 andtwo AAV inverted terminal repeats (ITRs) were prone to deletions orrearrangements when the plasmid clones were propagated in commonly usedbacterial strains. After extensive testing, it was observed that thevector plasmids maintained their integrity in XL10 Gold cells. PCRamplification of the region spanning the repetitive glutamicacid-glycine coding sequence in the mouse or human RPGR-ORF15 cDNAproduced the expected 1.3 kb or 1.6 kb fragment in the vector plasmidsand all vector preparations. The PCR assay did not identify visibledeletion in most AAV vector preparations. However, minor deletions weredetected in two vector preparations. The full-length human RPGR-ORF15vector comprised SEQ ID NO: 15 and encoded the amino acid sequence ofSEQ ID NO: 25 (functional variant of wild-type human RPGR). Thefull-length mouse RPGR-ORF15 vector comprised SEQ ID NO: 24 and encodedthe amino acid sequence of SEQ ID NO: 23 (mouse RPGR).

Example 2

This example demonstrates the AAV vector-mediated expression ofRPGR-ORF15 proteins.

To test whether the vectors of Example 1 mediate full-length RPGR-ORF15protein expression in mouse retina, immunoblot analyses of the retinallysates from vector-treated Rpgr-KO mice were performed. Using anantibody against the C-terminus of the mouse RPGR-ORF15, RPGR proteinwas identified in the Rpgr-KO retina treated with the AAV8-mRpgr vector.The retinal lysate from an Rpgr-KO mouse injected subretinally with1×10⁹ vg AAV8-mRpgr vector revealed a ˜200 kDa protein bandcorresponding to the full length RPGR-ORF15 protein, which is identicalto that detectable in a wild-type (WT) C57/B16 mouse retina. Thisprotein was identical in size to the wild type (WT) RPGR protein,suggesting the ability of the vector to produce a full-length mouseRPGR-ORF15 protein. Similarly, AAV8-hRPGR vector was able to generatethe full-length human RPGR-ORF15 protein in the Rpgr-KO retina. Theretinal lysate from an Rpgr-KO mouse injected subretinally with 1×10⁹ vgAAV8-hRPGR vector revealed a ˜200 kDa protein band corresponding to thefull length RPGR-ORF15 protein, identical to that from a commerciallysourced human retinal lysate. No signal was detected in the lane thatincluded 1/10th the amount of retinal lysate from the vector-injectedeye, revealing the sensitivity limits of the assay. A set of lowermolecular weight proteins in the AAV8-hRPGR-treated retina were alsodetected when an antibody against the epitopes upstream of the ORF15exon was employed. Although the possibility that these shorter proteinswere caused by the deletions in the ORF15 exon in AAV vectorpreparations cannot be ruled out, these shorter proteins could also bealternatively spliced or C-terminal truncated forms of RPGR-ORF15, asobserved in WT mouse retina (Hong et al., Invest. Ophthalmol. Vis. Sci.,43: 3373-3382 (2002)). Shorter proteins have also been identified inAAV8-mRpgr-treated Rpgr-KO retina when an antibody against the epitopesupstream of the ORF15 exon of mouse RPGR was used.

RPGR-ORF15 protein localizes to the connecting cilia of thephotoreceptors in mouse and other mammalian species (Hong et al., Proc.Natl. Acad. Sci., 97: 3649-3654 (2000); Hong et al., Invest. Ophthalmol.Vis. Sci., 44: 2413-2421 (2003)). To test whether the vector-expressedmouse and human RPGR-ORF15 also localize to the connecting cilia, abrief on-slide fixation of frozen retinal section using 1% formaldehydeinstead of the conventional 4% paraformaldehyde (PFA) fixation wasemployed for immunofluorescence assay, since the latter blocks antibodypenetration to this region (Hong et al., Invest. Ophthalmol. Vis. Sci.,44: 2413-2421 (2003)). Similar to the WT protein, the vector-expressedRPGR-ORF15 mainly appeared as dots between the inner (IS) and outersegments (OS) corresponding to the location of the connecting cilia. Inaddition to its connecting cilia localization, the vector-expressedRPGR-ORF15 was frequently observed at the IS, and sometimes at thenuclei and the synaptic terminals of the photoreceptors when theconventional 4% PFA fixation was used. When the modified fixation methodwas used, RPGR immunostaining was observed at the connecting ciliaregion in both WT and the AAV8-mRpgr treated retina. When the regularfixation method was used, RPGR was undetectable in the WT retina, butthe staining was observed at the IS, ONL and the synaptic region in theAAV8-mRpgr treated retina. This apparent mis-localization of RPGR-ORF15seems to be vector-related as it was also observed in AAV5 RPGRvector-treated canine retina (Beltran et al., Proc. Natl. Acad. Sci.,109: 2132-2137 (2012)) but not in the WT mouse retina. Without beingbound to a particular theory or mechanism, it is believed thatoverexpression of the protein by using a relatively high vector dose(1×10⁹ vector genomes (vg)) and a strong RK promoter may account forthis observation. No detectable RPGR-ORF15 expression was observed inother retinal layers owing to the photoreceptor specificity of the RKpromoter. The mouse Rpgr-ORF15 delivered by the AAV9 vector expressedthe protein at a similar level as the AAV8 vector when same dose wasused, and the protein was targeted to identical subcellularlocalization.

Example 3

This example demonstrates the short-term dose-toxicity profile of themouse and human RPGR-ORF15 vectors.

To define the dose range for a long-term efficacy study, a short-termvector toxicity study was conducted over a 4-month period. Eightweek-old Rpgr-KO mice were unilaterally injected with 1×10¹⁰ or 1×10⁹ vgof AAV8-hRPGR or AAV8-mRpgr vector per eye through sub-retinalinjection. The fellow eye was used as control by injecting the samevolume of vehicle. Dark- and light-adapted ERG were recorded to evaluateresponses from rod and cone photoreceptors at 4 months post-injection(PI) before sacrificing the mice for immunofluorescence analyses. Due tothe slow retinal degeneration in the Rpgr-KO mouse line, a therapeuticeffect at 4 months after vector treatment was not expected.

No statistically significant difference was observed between the vectorand the vehicle-treated eyes in ERG amplitudes of dark-adapted a-, b-and light-adapted b-waves in mice that received 1×10⁹ vg AAV8-hRPGR orAAV8-mRpgr vector. However, remarkably lower amplitudes of all three ERGcomponents were observed in eyes receiving 1×10¹⁰ vg vectors, while1×10⁹ vg/eye vector administration did not cause significant ERG change,indicating the vector toxicity at the high dose. This observation wascorroborated by immunofluorescence analyses of the vector-treatedretinas. Since the retina sections were fixed in 4% PFA before freezing,only the pool of mis-localized recombinant RPGR at IS was detected (asexplained above). More intensive RPGR-ORF15 expression was observed in1×10¹⁰ vg vector-treated retina, accompanied by a much thinner outernuclear layer (ONL) and shorter IS. In contrast, the ONL thickness ofthe 1×10⁹ vg vector-treated retina did not reveal marked difference fromthe vehicle-treated retina. Both the ERG and immunofluorescence analysesindicate that the dose of 1×10⁹ vg per eye is well tolerated, while1×10¹⁰ vg is toxic to the mouse retina. Without being bound to aparticular theory or mechanism, it is believed that a combinationaleffect of overexpressing the RPGR-ORF15 protein, the large amount of AAVcapsid protein and vector DNA that exceeds the processing capacity ofthe retinal cells might account for the toxicity of the high vectordose. Therefore, the dose of 1×10¹⁰ vg per eye was not included in thesubsequent long-term efficacy study.

Example 4

This example demonstrates the treatment effect in the Rpgr-KO micefollowing gene delivery of mouse Rpgr-ORF15.

To test whether the mouse Rpgr-ORF15 cDNA delivered by AAV8 or AAV9vector was efficacious, the vectors were injected in the subretinalspace of 6-8 week-old mice at doses ranging from 1×10⁸ to 1×10⁹ vg pereye. Unilateral vector injection was performed on each mouse and thecontralateral eye was injected with the vehicle. Due to the slowprogression of retinal degeneration in the Rpgr-KO mice (Hong et al.,Proc. Natl. Acad. Sci., 97: 3649-3654 (2000); Hong et al., Invest.Ophthalmol. Vis. Sci., 46: 435-441 (2005)), a longitudinal ERGmonitoring was performed during the 18-month follow-up period. Given thelarge variation in ERG amplitudes among individual mice, paired t-testwas employed throughout the study to compare the vector- and thevehicle-treated eyes. Among all cohorts, mice receiving 3×10⁸ vgAAV9-mRpgr displayed the strongest therapeutic effect in vector-treatedeyes. Although only a slight improvement was observed in thevector-treated eyes at 12 months PI, the therapeutic effect became morepronounced at 18 months PI, in which significantly larger amplitudeswere observed for dark-adapted a-wave and light-adapted b-wave inresponse to increasing intensities of flash stimuli. These eyes alsodisplayed significantly larger dark-adapted b-wave amplitude, which wasnot seen at 12 months PI, reflecting a better preservation of visualsignaling to the bipolar cells. In all seven mice that survived 18 monthmonitoring, each individual animal exhibited greater dark-adapted a-, b-and light-adapted b-wave amplitudes elicited from the highest flashintensity in the vector-treated eye. Cohorts receiving other vectordoses (1×10⁹ vg/eye AAV8-, 1×10⁸ vg/eye AAV8-, or 1×10⁹ vg/eyeAAV9-mRpgr vector) displayed suboptimal rescue at 18 months PI comparedwith the one receiving 3×10⁸ vg AAV9-mRpgr vector.

Functional rescue of the vector-treated retinas was correlated withtheir structural improvement. Much thicker ONL was observed in 3×10⁸ vgAAV9-mRpgr treated eyes than the control eyes, as revealed by opticalcoherence tomography (OCT) retinal imaging at 18 months PI. Theincreased retinal thickness in the vector-treated eye was observedwithin a ˜1.0 mm² diameter field of view, except for the central areawhere optic nerve head (ONH) was located. Subsequent to OCT,immunofluorescence analyses of treated mouse retina showed thatAAV-mediated RPGR expression spanned roughly half of the cross-section.Vector-treated eyes preserved significantly more rows of photoreceptorsthan control eyes, consistent with the OCT findings. Seven to ten rowsof photoreceptors were maintained in a majority of the vector-treatedeyes, compared with four to six rows in the control eyes. Themeasurements of ONL thickness at 500 μm intervals along the vertical(dorsal-ventral) meridian on retinal sections further corroborated thesefindings. The average ONL thickness at different locations of thevector-treated retinas ranged between 31.7 μm and 43.5 μm, while itranged between 19.0 μm and 28.3 μm in the control retinas. The treatmenteffect appeared to be even more pronounced at 24 months PI in one groupof mice receiving 1×10⁹ vg AAV8-mRPGR injection. While the ONL of thecontrol retina almost disappeared in the superior portion and only 1 to3 rows of photoreceptors remained in the inferior retina, 6-8 rows ofphotoreceptors survived in inferior areas of the vector-treated retinawhere RPGR was expressed.

Opsin mis-localization (because of altered transport/targeting to outersegments) is detectable in animal models and in a human carrier withRPGR mutations. Immuno-staining was performed on the 3×10⁸ vgAAV9-mRpgr-treated retina at 18 months PI to assess whether opsintransport could be corrected by Rpgr gene delivery. In the WT retina,M-cone opsin is found exclusively in the outer segments of cone cells.In the vehicle-treated Rpgr-KO retina, M-opsin was detected in innersegments as well as in the perinuclear and synaptic regions in additionto the outer segments. More M-opsin was present in photoreceptor innersegments in the superior retina compared with the inferior retina.Without being bound to a particular theory or mechanism, it is believedthat this is probably due to the superior to inferior gradient ofM-opsin expression. This M-opsin transport to outer segments waspartially rescued in the vector-treated retina at 18 months PI.

Rhodopsin localized only to the rod outer segments in WT retina. Thismis-localization was not seen in the RPGR-expressed area in thevector-injected KO retina. Rhodopsin was additionally observed at the ISand perinuclears in the vehicle-injected KO retina. In the young Rpgr-KOmouse retina, rhodopsin was appropriately localized; however, rhodopsinimmunostaining was detected in the inner segments and perinuclear regionin 20 month-old vehicle-injected Rpgr-KO retina. Rhodopsin localizationwas corrected in the areas expressing RPGR-ORF15 in the vector-treatedretina of Rpgr-KO mice.

Example 5

This example demonstrates the treatment effect in the Rpgr-KO micefollowing gene delivery of human RPGR-ORF15.

As a potential vector candidate for future human trials, AAV8-hRPGR wastested for its efficacy in Rpgr-KO mice with four different doses;3×10⁹, 1×10⁹, 3×10⁸ and 1×10⁸ vg per eye. Six to 8 week-old mice wereinjected with the vector subretinally and ERG was performed at 12 and 18months PI. Among the four dose groups, optimal outcome was observed in1×10⁹ vg-treated group. At this dose, the vector-treated eyes displayedsignificantly higher amplitudes dark-adapted a-, b-wave andlight-adapted b-wave were observed in response to increasing intensitiesof flash stimuli at 18 month PI, indicating the rescue of retinalfunction in the Rpgr-KO mouse following human RPGR-ORF15 gene delivery.All 11 mice that survived the 18 month monitoring period exhibitedhigher light-adapted b-wave amplitudes in vector-treated eyes; of these,10 and 9 mice respectively displayed higher dark-adapted b-wave anddark-adapted a-wave.

Mice receiving 3×10⁹ vg vector demonstrated much lower ERG amplitudes inthe vector-treated eyes than control eyes at 18 month PI; however, thisdifference was not statistically significant at 12 month PI indicatingthe long-term toxicity at this dose. The 3×10⁸ vg and 1×10⁸ vgvector-treated eyes did not show a difference from control eyes for ERGamplitudes. To investigate whether the therapeutic effect was too smallto be detected, ERG was performed again 6 months later when these micewere almost 26 month-old. ERG improvement was still not observed in thevector-treated eyes in both dose groups, indicating that these twovector doses were too low to achieve functional rescue in the Rpgr-KOmice.

OCT retinal imaging was performed on the Rpgr-KO mice treated with 1×10⁹vg AAV8-hRPGR vector at 18 months PI. Much thicker ONL was observed inthe vector-treated retinas than the controls, and the thickness of thewhole retina in the vector-treated eyes was greater than the controlswithin ˜1.0 mm² diameter field of view. By immunofluorescence analyses,vector-treated retina revealed hRPGR expression in about half of thearea of the cross section. Consistent with the OCT findings, more rowsof photoreceptors were preserved in the vector-treated retina than inthe control and measurements of ONL thickness across 4 mm of retinaalong the vertical (dorsal-ventral) meridian corroborated theseobservations. The average ONL thickness at different locations of thevector-treated retinas ranged between 21.2 μm and 33.4 μm, whilevehicle-treated retinas had ONL between 14.3 μm and 24.1 μm.Immunofluorescence analyses of the retina receiving a lower vector dose(3×10⁸ vg) revealed hRPGR staining in a smaller area; however, morephotoreceptors were preserved in this area compared to the adjacentregion. Therefore, preservation of photoreceptors in vector-transducedareas was still achieved in the lower dose groups despite the lack ofoverall functional preservation as evaluated by full-field ERG.Rhodopsin was only observed in rod OS of WT retina, but additionalstaining was observed at the IS, perinuclear and synaptic terminals inthe vehicle-treated Rpgr-KO retina. This rhodopsin mis-localization wasnot detected in areas with appropriate hRPGR expression in thevector-treated (1×10⁹ vg AAV8-hRPGR) retina, while it was apparent inthe control retina.

Example 6

This example demonstrates the rescue of retinal function and structurefollowing RPGR-ORF15 gene delivery to older Rpgr-KO mice.

To assess whether retina with more substantial degeneration would stillbenefit from the treatment, 3×10⁸ vg AAV8-mRPGR was subretinallyinjected into 1 year-old Rpgr-KO mice. No appreciable difference wasobserved between vector- and vehicle-treated eyes when tested at 5months PI. However, the ERG rescue became apparent in vector-treatedeyes at 11 months PI, when mice were 23 month-old. OCT imaging revealedmuch thicker ONL in the vector-injected retina than in thevehicle-injected control; this finding was subsequently confirmed bymorphology analyses. Substantially more rows of photoreceptors wereobserved in the area with RPGR expression in the vector-injected eye ascompared to control retina. These results suggest that the Rpgr-KO mousecould still respond favorably to Rpgr gene delivery even when treated atan advanced age with active degeneration in the retina.

Examples 7-12

The following materials and methods were employed for Examples 7-12:

Generation of the Rp2-KO Mouse Line and Animal Husbandry

An Rp2-KO mouse line was created by crossing an Rp2^(flox/flox) linewith a ubiquitous Cre expressing line (CAG cre and Zp3 Cre line). All ofthe mice were maintained as described in the “mouse line and husbandry”section of the methods described for Examples 1-6 above.

AAV Vector Construction and Production

A synthetic human RP2 cDNA (SEQ ID NO: 1) with ClaI and XhoI sites wascloned in a vector with a rhodopsin kinase promoter (SEQ ID NO: 10), achimeric (β-globin/CMV) intron (SEQ ID NO: 9), and a β-globin poly-Atail (SEQ ID NO: 7). AAV type 2 inverted terminal repeats (ITRs) (SEQ IDNOs: 12 and 13) were used in the AAV vector construction. The left ITR(ITR near the promoter region) (SEQ ID NO: 13) was mutated to eliminatethe terminal resolution site and AAV D sequence to make it aself-complementary AAV vector.

Triple-plasmid transfection to HEK293 cells was used to produce AAVvectors as described in Grimm et al., Blood, 102: 2412-2419 (2003). Theself-complementary human RP2 construct (SEQ ID NO: 14) was packaged intoan AAV8 capsid (SEQ ID NO: 5). The amount of virus was measured by realtime PCR using the following primer and fluorescent labeled probes:

(SEQ ID NO: 20) Forward primer (5′-3′):-GCACCTTCTTGCCACTCCTA;(SEQ ID NO: 21) Reverse primer (5′-3′):-GACACAGCACCAGGCTAAATCC; and(SEQ ID NO: 22) Probe(5′-3′):-CGTCCTCCGTGACCCCGGC.Sub-Retinal Injection

Subretinal injection was performed as described in Sun et al., GeneTherapy, 17: 117-131 (2010) with some modifications. Mice wereanesthetized with an intra-peritoneal injection of ketamine (80 mg/Kg)and xylazine (8 mg/Kg). The pupils were dilated with topical atropine(1%) and tropicamide (0.5%). Proparacaine (0.5%) was used as topicalanesthesia. Surgery was performed under an ophthalmic surgicalmicroscope. An 18 gauge hypodermic needle was used to make a smallincision in the cornea adjacent to the limbus. A 33 gauge blunt needlefitted to a Hamilton syringe was inserted through the incision whileavoiding the lens and pushed through the retina. A 1 μl of samplecontaining either therapeutic vector or a saline solution was deliveredsubretinally. Therapeutic vectors were given in the right eye andvehicle was given in the fellow eye. Visualization during injection wasaided by addition of fluorescein (100 mg/ml AK-FLUOR (fluoresceininjection, USP), Alcon, Fort Worth, Tex., USA) to the vector suspensionsat 0.1% by volume.

ERG

ERGs were performed using ESPIONE E2 electroretinography system. Micewere dark adapted overnight. Pupils were dilated with topical atropine(1%) and tropicamide (0.5%). The mice were anesthetized with anintra-peritoneal injection of ketamine (80 mg/Kg) and xylazine (8mg/Kg). All the above procedures were done in dim red light. ERGs wererecorded from both eyes using gold wire loops with 0.5% proparacainetopical anesthesia and a drop of 2% methylcellulose for cornealhydration. A gold wire loop placed in the mouth was used as reference,and a ground electrode was placed on the tail. Dark-adapted ERG was donein the dark with brief white flash intensity ranging from −4 log cd-s/m²to +3 log cd-s/m². Light-adapted ERG was recorded after light adaptationof 2 min with white light. ERG recording was done with brief white flashintensity ranging from −0.53 log cd-s/m² to +2 log cd-s/m² with abackground white light of 20 cd/m² intensity. The flicker response wastaken with 10 Hz light flicks. For recording M and S-opsin mediated ERGresponse, the mice were first light adapted for 2 minutes in a greenlight with 20 cd/m² light intensity. ERG was recorded by alternatinggreen and ultraviolet (UV) flash with intensity ranging from −0.52 to +2log cd-s/m² for green flash and −4 to −0.52 log cd-s/m² for UV flashwith a background green illumination of 20 cd/m². ERG was recorded fromRp2-KO mice treated with different vector doses and littermate wild typemice.

Determination of Visual Acuity

Visual acuity of the mice was determined by an optokinetic test in anoptokinetic reflex (OKR) arena developed by Cerebral Mechanics followingthe protocol described in Douglas et al., Vis. Neurosci., 22: 677-684(2005) and Prusky et al., Invest. Ophthalmol. Vis. Sci., 45: 4611-4616(2004). Briefly, the mouse was placed in the center of a closed OKRarena surrounded by four computer screens and a camera on top to monitorthe movement of the animal. The computer screens created a virtual imageof a rotating drum with sine waves grating in a 3D confirmation. Thetracking of the gratings by the mouse was scored by its head and neckmovement. The spatial frequency of the grating was controlled andmonitored by OPTOMOTRY software (Version 14). The maximum spatialfrequency in a 100% background contrast which generated a trackingmovement by the animal was recorded for each eye.

Immunoblotting

Whole retinal lysate was prepared in RIPA buffer with protease inhibitorcocktail by sonication. The lysate was cleared by centrifugation, andthe protein was estimated using Bradford reagent. Approximately 20 μg ofprotein was used in every lane of 10% denaturing protein gel (BioRad,Hercules, Calif.). Immunoblotting was performed by a standard procedureusing the primary antibody against human RP2 and β-actin. The proteinswere visualized with peroxidase-conjugated secondary antibody withappropriate reagents.

Immunohistochemistry

For immunohistochemistry, mice were euthanized and eyes were enucleated.The eyes were fixed in 4% PFA solution for 1-2 hours, passed through aseries of sucrose solution for cryo-protection, and were flash frozen inOCT solution. A series of retinal sections having a thickness of 12 μmwas cut through the eyes in a superior-inferior pole orientation bycryostat. The sections were stained with specific antibody (M & S coneopsin, rhodopsin, PNA, RP2) using the protocol described below. Briefly,sections were blocked in 5% goat serum in PBS containing 0.1% TritonX-100 (PBST) for 1 h, followed by incubation in primary antibodiesdiluted in 2% goat serum at 4° C. overnight. Sections were washed threetimes in PBST and incubated with fluorochrome-conjugated secondaryantibodies and 0.2 μg/ml DAPI for 1 h. Sections were washed again withPBS and mounted in FLUOROMOUNT-G mounting medium (SouthernBiotech,Birmingham, Ala.). Sections were visualized, and images were captured ona confocal scanning microscope LSM700 (Zeiss, Germany).

To prepare a flat mount, retina enucleated eyes from euthanized micewere first incubated in chilled PBS solution for 15 minutes over ice.Afterwards, eyeballs were then squeezed gently several times to detachthe retina. The eyeballs were then fixed in 4% PFA for 1 hour, and theretina was separated from other parts of eye, washed in PBS containing0.1% Triton, blocked in 5% goat serum in PBST for 4 hrs, followed byincubation in primary antibodies diluted in 2% goat serum at 4° C.overnight. The retina was again washed 3 times (2 for 45 mins each and 1for 1 hr) in PBST, and incubated with fluorochrome-conjugated secondaryantibodies for 4 hrs. The sections were again washed in PBST asdescribed above and mounted in FLUOROMOUNT-G mounting medium(SouthernBiotech, Birmingham, Ala.) with the photoreceptor layers facingup. Images were captured on a confocal scanning microscope LSM700(Zeiss, Germany).

Statistical Analysis

Two-tailed paired and unpaired t-test was used to compare outcomes invector-treated versus vehicle-treated eyes. GRAPHPAD Prism 6 software(GraphPad Software, La Jolla, Calif.) was used for statistical analysis.

Example 7

This example demonstrates that a Rp2-KO mouse exhibits a progressivedegeneration of cone photoreceptors.

An Rp2-KO mouse model was generated by crossing Rp2^(flox/flox) micewith either a CAG Cre transgenic mouse line as reported in Li et al.,Invest. Ophthalmol. Vis. Sci., 54: 4503-4511 (2013) or a ZP3 Cre mouseline. In ZP3-Cre line, Cre is expressed specifically in oocytes.Although Cre is ubiquitously expressed in CAG-Cre line, Cre expressionon its own does not affect retinal function, as shown in Li et al.,Invest. Ophthalmol. Vis. Sci., 54: 4503-4511 (2013). Addition of CAG-Cretransgene even in the Rp2-KO line has no further impact of the retina.RP2 exon 2 was deleted in the resulting Rp2-KO mouse line, and no RP2protein was detectable in the retina and other tissues (Li et al.,Invest. Ophthalmol. Vis. Sci., 54: 4503-4511 (2013)). To evaluate theprogression of retinal degeneration in this model, a large cohort of themice was monitored along with their wild-type (WT) littermates byelectroretinogram (ERG) during an 18-month period. Amplitude ofdark-adapted a-wave is mainly contributed by rods. Though cone-deriveda-wave is relatively small under light-adapted conditions, b-wave isproduced by the inner retina neurons and reflects the activity of conesystem. Therefore, dark-adapted a-wave and light-adapted b-wave wereused to represent rod and cone functions, respectively. Consistent withprevious observations (Li et al., Invest. Ophthalmol. Vis. Sci., 54:4503-4511 (2013); Zhang et al., FASEB J., 29: 932-942 (2014)), theRp2-KO mice exhibited significantly reduced amplitudes of dark-adapteda-wave and light-adapted b-wave through the entire duration of theexperiments. The stimulus intensities for dark- and light-adapted ERGswere −4.0 to 3.0 and −1.0 to 2.0 log cd s/m², respectively. This ERGamplitude reduction happened even as early as 1 month of age in a smallgroup of monitored mice, indicating functional impairment of both rodsand cones at an early age. However, measurement of the ratio of KO to WTfor ERG amplitudes revealed distinct dynamics between rod and conefunctions in the KO mice over the 18-month period. The dark-adapteda-wave amplitude of KO relative to that of WT remained stable after 4months of age without additional reduction, whereas the KO to WT ratioof light-adapted b-wave amplitude continuously declined at a nearlyconstant rate between 4 and 18 months. As a result, about 78% of rod ERGamplitude was preserved at 18 months compared with only 33% of cone ERGamplitude, demonstrating a more severe impairment of cone function inthe KO mice. Additionally, the relatively mild impairment in rodfunction did not significantly impact the inner retina function since nodifference was observed between KO and WT mice for dark-adapted b-wavewith dim flash intensity. The progressive worsening of cone function inthe KO retina was also reflected by the pronounced reduction in theflicker response.

A significant alteration in light-adapted b-wave kinetics was observedin Rp2-KO mice when compared with their WT littermates, consistent withthe findings in Zhang et al., FASEB J., 29: 932-942 (2014). To assessthe response kinetics, the time it took the b-wave to rise to 50% of itspeak amplitude (T_(50 rise)), the time it took to reach the peakamplitude (T_(max), same as implicit time) and the time to fall from thepeak to 50% of the peak amplitude (T₅₀ decay) were measured. The4-month-old KO mice displayed significantly longer time course in allthree measurements than their WT littermates. In particular, thekinetics of the b-wave falling phase was distinctly slower in KO micecompared with WT, as reflected by much longer T₅₀ decay time (40.1±1.6ms in WT versus 81.8±5.5 ms in KO, mean±SEM). This alteration inkinetics began early, as longer T_(max) and T₅₀ decay were alreadyobserved in 1-month-old KO mice. The kinetics difference between KO andWT mice appeared to be specific to the cone system, as no such changewas observed in dark-adapted b-wave under low flash stimulus intensity,which reflects the function of pure rod system.

Consistent with the cone-mediated ERG findings, very few M- or S-conephotoreceptors were observed at 18 months of age compared with the WTretina, indicating a severe cone degeneration in the Rp2-KO retina. Incontrast, no detectable change in the thickness of the rod-dominantphotoreceptor layer was seen during the 18-month period. In addition,distribution of rhodopsin in the Rp2-KO mice remained the same as the WTmouse, with rhodopsin mainly being detected at the OS, its naturallocalization. The thickness of rod-dominant photoreceptor layer was notsignificantly altered even in the 18-month-old KO retina. The relativelymild rod dysfunction in the KO mice is likely caused by somewhatdisorganized OS as revealed by ultrastructural analysis (Li et al.,Invest. Ophthalmol. Vis. Sci., 54: 4503-4511 (2013)). Roddisorganization was not captured by light microscopy analyses.

Example 8

This example demonstrates that an AAV8 vector carrying human RP2 cDNAmediates stable RP2 expression in mouse photoreceptors.

To develop gene therapy for RP2-associated retinal degeneration, an AAVvector carrying a human RP2 expression cassette was designed andconstructed. The vector (SEQ ID NO: 14) was composed of aphotoreceptor-specific human rhodopsin kinase (RK) promoter (SEQ ID NO:10), a CMV and human β-globin hybrid intron (SEQ ID NO: 9), a human RP2cDNA (SEQ ID NO: 1), and the human β-globin polyadenylation site (SEQ IDNO: 7), flanked by two inverted terminal repeats (ITRs) from AAVserotype 2 (AAV2) (SEQ ID NOs: 12 and 13). The RK promoter has beenshown to be able to drive cell-specific transgene expression in bothrods and cones in mice (Khani et al., Invest. Ophthalmol. Vis. Sci., 48:3954-3961 (2007)). The length of this human RP2 expression cassette wassmaller than 2 kilo-basepairs (kb), a size that fit well with aself-complementary (sc) AAV vector that is capable of mediating earlieronset and more efficient transgene expression than a conventionalsingle-stranded (ss) vector. To construct a sc vector, one WT ITR wasreplaced with a mutant ITR in which the terminal resolution site and theAAV D sequence were deleted. The vector was packaged into AAV8 (SEQ IDNO: 5), a serotype that transduces photoreceptors of mouse and non-humanprimate very efficiently, and was designated as AAV8-scRK-hRP2 vector(SEQ ID NO: 14), encoding the amino acid sequence of SEQ ID NO: 2 (humanRP2).

To test whether the vector mediates human RP2 expression, the vector wasinjected subretinally into RP2-KO mice, and the retinal extracts weresubjected to immunoblot analyses 4 weeks later with a polyclonalantibody recognizing both mouse and human RP2 proteins. While thevehicle-treated retina did not reveal any RP2-specific band, thevector-treated retina exhibited a band at the expected molecular weightof ˜40 kDa, identical to that of the human retinal lysate, indicatingthe vector's ability to express human RP2 protein. The endogenous mouseRP2 protein in the WT retina migrated slightly faster than the humancounterpart. Without being bound to a particular theory or mechanism, itis believed that because mouse and human RP2 proteins contain similarnumbers of amino acid residues (a.a.) (350 a.a. for human RP2 and 347a.a. for mouse RP2), this electrophoretic mobility difference mightreflect the different amino acid compositions and/or post-translationalmodifications of the two proteins.

Immunofluorescence analysis was performed to examine the cellular andsubcellular localization of the vector-expressed RP2 protein in theretina. Endogenous mouse RP2 protein was detected in multiple layers inWT retina, including the IS, outer and inner plexiform layers (OPL andIPL), which was not seen in the Rp2-KO retina. The vector-expressedhuman RP2 protein was primarily localized at the IS and nuclei ofphotoreceptors, but was not observed in any other layers of the retina.Without being bound to a particular theory or mechanism, it is believedthat this is probably due to the specificity of the RK promoter and theinaccessibility of the vector to the inner retinal layers followingsubretinal administration. The vector-mediated RP2 expression wassustained throughout the entire 18-month study period without detectableloss. No expression of RP2 protein was detected in Rp2-KO mice injectedwith vehicle.

Example 9

This example demonstrates that RP2 gene delivery with a wide dose rangerescues cone function in Rp2-KO mice.

To test the treatment effect of the AAV8-scRK-hRP2 vector, 4 to 6week-old Rp2-KO mice were administered subretinally with the vector atthree doses; 1×10⁸, 3×10⁸ and 1×10⁹ vector genomes (vg) per eye. Themice received unilateral vector injections, with the contralateral eyesreceiving vehicle injections as controls. A longitudinal ERG monitoringwas performed until the mice reached 18 months of age. Given the largevariation in ERG amplitudes among individual mice, paired t-test wasemployed throughout the study to compare the vector- and thevehicle-treated eyes. Cone function rescue was achieved in the 1×10⁸ andthe 3×10⁸ vg/eye dose groups as reflected by the significantly higherlight-adapted ERG b-wave amplitude in vector-treated eyes as compared tovehicle-injected fellow eyes. This therapeutic effect was observed asearly as at 4 months of age, the earliest time point of examination, andit lasted through the entire duration of the study period. Almost 75%(71-78%) of photopic b-wave amplitude was preserved in vector-treatedeyes at 18 months in contrast to only ˜28% remaining in the controleyes. In addition to preservation of light-adapted b-wave amplitude, thetreatment completely corrected the alteration of b-wave kinetics in theKO retina, as revealed by nearly normal T₅₀ rise, T_(max) and T₅₀ decaymeasured in the vector-treated eyes of 4-month-old mice. The 1×10⁸vg/eye vector treatment appeared not to be toxic to rods, as nosignificant difference was observed between vector- and vehicle-treatedeyes in rod ERG response (dark-adapted a-wave) during the 18-month studyperiod. Similarly, 3×10⁸ vg/eye vector treatment had no obvious effecton rods in general, although slightly lower dark-adapted response wasobserved at certain time points. The lack of effect on rods may beexplained by early onset (within 1 month of age and before vectoradministration, data not shown), through slower progression offunctional impairment in rods of Rp2-KO mice.

The effectiveness of 1×10⁸ and 3×10⁸ vg/eye vector treatment promptedexploration into whether a lower dose could still be functional.Therefore, the vector was administered to one group of mice at a dose of5×10⁷ vg/eye, and the treated mice were examined by ERG at 6.5 and 18months of age. Significantly higher light-adapted b-wave amplitude wasobserved in the vector-treated eyes as compared to the control eyes,indicating the vector's potency at this low dose. The cone functionrescue was not biased toward M- or S-cones, since the vector-treatedeyes displayed comparable preservation of M- and S-cone-driven ERGresponses.

To determine if RP2 gene delivery could result in a better visualacuity, mice treated with 1×10⁸ vg or 3×10⁸ vg vector were subjected toan optokinetic test under photopic conditions at 19 months of age.Although lower than WT controls, the visual acuity of the vector-treatedeyes was significantly higher than that of the vehicle-treated eyes,indicating an improvement in cone-mediated visual behavior in RP2-KOmice by the treatment.

Example 10

This example demonstrates that RP2 gene delivery with a wide dose rangerescues cone function in Rp2-KO mice.

M-opsin localized to OS in WT cones but was found mis-localized to IS,peri-nuclei, and synaptic terminals in vehicle-treated Rp2-KO cones,consistent with previous findings (Li et al., Invest. Ophthalmol. Vis.Sci., 54: 4503-4511 (2013)). In addition, the number of M-cones invehicle-treated KO retina appeared to be reduced at 6.5 months of agecompared to WT retina, indicating substantial cone degeneration.However, in vector treated-retina, the M-opsin mis-localization wasalleviated, and more M-cone cells were preserved. Normal subcellularlocalization of M-opsin was observed in vector-treated retina,suggesting that the treatment either prevented or reversed M-conemis-trafficking. Similarly, more S-cones were observed in vector-treatedretina, although no detectable S-opsin mis-localization was seen ineither vehicle or vector-treated KO eyes. Consistent with the findingsof Zhang et al., FASEB J., 29(3):932-42 (2015), cone PDE6 expressionwere almost undetectable in the outer segments of vehicle-treated Rp2-KOretina, whereas vector-treated retina retained near normal expression ofthe protein in the outer-segments. Localizations of two rod-specificproteins, rhodopsin and PDE6β, were also examined. These two proteinswere mainly localized at the OS of photoreceptors in WT retina, andtheir expression or localization in KO retina was not affected by vectortreatment.

Cone rescue was more pronounced in the treated eyes at the final18-month time point, as revealed by a significantly higher number ofpeanut agglutinin (PNA)-stained cells in both superior and inferiorretina compared with those of the control eyes. Immunofluorescenceanalyses of both retinal whole-mounts and sections revealedsignificantly higher number of M- and S-cones in vector-treated KOretina than the vehicle-treated retina.

Example 11

This example demonstrates that late RP2 gene delivery maintains conefunction and viability in Rp2-KO mice.

Impairment of cone function starts before 1-month of age in the Rp2-KOmouse model (Example 7; Li et al., Invest. Ophthalmol. Vis. Sci., 54:4503-4511 (2013)). To assess whether Rp2-KO mice with more advanced conedysfunction would still benefit from the treatment, the vector wasadministered to 10-month old Rp2-KO mice at a dose of 3×10⁸ vg/eye, andtheir retinal function and structure was examined when they reached18-month of age. The vector-treated eyes displayed significantly higherlight-adapted b-wave amplitude than vehicle-treated eyes as compared tovehicle-treated eyes, although no difference was seen in rod ERG.Consistent with this, substantial M- and S-opsin and conePDE6-expressing cells were observed in the vector-treated retina, incontrast to the vehicle-treated retina.

Example 12

This example demonstrates an effective dosage of the RP2 vector for usein Rp2-KO mice.

Vector doses ranging from 5×10⁷ to 3×10⁸ vg/eye were found to beefficacious in rescuing the function and viability of conephotoreceptors in Rp2-KO mice, as described above. These doses did notseem to affect rod function during the 18-month study period, althoughslight reductions were seen at 8 and 12 months in the 3×10⁸ vg dosegroup. Most toxicity was confined to the dark-adapted ERG response,indicating transient toxicity of the vector at this dose towards rods.However, cone function was significantly improved at the dose of 3×10⁸vg. In contrast, mice that received the dose of 1×10⁹ vg/eye exhibitedsignificantly impaired rod function at all the time points of ERGexamination (4 months, 8 months, and 18 months), as reflected byremarkably reduced amplitudes of dark-adapted a- and b-waves. Althoughthis dose preserved cone function at 4 and 8 months, this treatmentbenefit eventually diminished at 18 months. Without being bound to aparticular theory or mechanism, it is believed that this is probably dueto secondary cone cell death caused by eventual loss of rods.Immunofluorescence analysis of retinal sections at the final 18-monthtime point revealed much thinner or even diminished outer nuclear layerat multiple regions in the 1×10⁹ vg-treated eye, in contrast to noobvious changes in the 1×10⁸ vg-treated eye. Therefore, the dose of1×10⁹ vg/eye was toxic to the retina.

All references, including publications, patent applications, andpatents, cited herein are hereby incorporated by reference to the sameextent as if each reference were individually and specifically indicatedto be incorporated by reference and were set forth in its entiretyherein.

The use of the terms “a” and “an” and “the” and “at least one” andsimilar referents in the context of describing the invention (especiallyin the context of the following claims) are to be construed to coverboth the singular and the plural, unless otherwise indicated herein orclearly contradicted by context. The use of the term “at least one”followed by a list of one or more items (for example, “at least one of Aand B”) is to be construed to mean one item selected from the listeditems (A or B) or any combination of two or more of the listed items (Aand B), unless otherwise indicated herein or clearly contradicted bycontext. The terms “comprising,” “having,” “including,” and “containing”are to be construed as open-ended terms (i.e., meaning “including, butnot limited to,”) unless otherwise noted. Recitation of ranges of valuesherein are merely intended to serve as a shorthand method of referringindividually to each separate value falling within the range, unlessotherwise indicated herein, and each separate value is incorporated intothe specification as if it were individually recited herein. All methodsdescribed herein can be performed in any suitable order unless otherwiseindicated herein or otherwise clearly contradicted by context. The useof any and all examples, or exemplary language (e.g., “such as”)provided herein, is intended merely to better illuminate the inventionand does not pose a limitation on the scope of the invention unlessotherwise claimed. No language in the specification should be construedas indicating any non-claimed element as essential to the practice ofthe invention.

Preferred embodiments of this invention are described herein, includingthe best mode known to the inventors for carrying out the invention.Variations of those preferred embodiments may become apparent to thoseof ordinary skill in the art upon reading the foregoing description. Theinventors expect skilled artisans to employ such variations asappropriate, and the inventors intend for the invention to be practicedotherwise than as specifically described herein. Accordingly, thisinvention includes all modifications and equivalents of the subjectmatter recited in the claims appended hereto as permitted by applicablelaw. Moreover, any combination of the above-described elements in allpossible variations thereof is encompassed by the invention unlessotherwise indicated herein or otherwise clearly contradicted by context.

The invention claimed is:
 1. An AAV vector comprising a nucleic acidcomprising a nucleotide sequence encoding RPGR-ORF15 or a functionalfragment or a functional variant thereof, wherein: (i) the vectorfurther comprises a CMV/human β-globin intron and/or a human β-globinpolyadenylation signal; and (ii) the nucleotide sequence encodingRPGR-ORF15 or a functional fragment or a functional variant thereof isunder the transcriptional control of a rhodopsin kinase promoter,wherein the rhodopsin kinase promoter comprises a nucleotide sequencethat is at least 99% identical to SEQ ID NO:
 10. 2. The vector accordingto claim 1, further comprising an AAV2 ITR or a functional fragmentthereof.
 3. The vector according to claim 1, comprising the nucleotidesequence of SEQ ID NO: 15 or
 26. 4. The vector according to claim 1,wherein the vector is an AAV8 or AAV9 vector.
 5. A pharmaceuticalcomposition comprising the vector of claim 1, further comprising apharmaceutically acceptable carrier.
 6. A method of treating orpreventing X-linked retinitis pigmentosa (XLRP) in a mammal in needthereof, the method comprising administering to the mammal the vector ofclaim 1 in an amount effective to treat or prevent XLRP in the mammal.7. A method of increasing photoreceptor number in a retina of a mammal,the method comprising administering to the mammal the vector of claim 1in an amount effective to increase photoreceptor number in the retina ofthe mammal.
 8. A method of increasing visual acuity of a mammal, themethod comprising administering to the mammal the vector claim 1 in anamount effective to increase visual acuity in the mammal.
 9. A method ofdecreasing retinal detachment in a mammal, the method comprisingadministering to the mammal the vector of claim 1 in an amount effectiveto decrease retinal detachment in the mammal.
 10. A method of increasingthe electrical response of a photoreceptor in a mammal, the methodcomprising administering to the mammal the vector of claim 1 in anamount effective to increase the electrical response of thephotoreceptor in the mammal.
 11. A method of increasing expression ofRPGR in a retina of a mammal, the method comprising administering to themammal the vector of claim 1 or a pharmaceutical composition comprisingthe vector in an amount effective to increase expression of RPGR in theretina of the mammal.
 12. A method of localizing a protein to rod outersegments in a retina of a mammal, the method comprising administering tothe mammal the vector of claim 1 or a pharmaceutical compositioncomprising the vector in an amount effective to localize the protein tothe rod outer segments in the retina of the mammal, wherein the proteinis rhodopsin or PDE6.
 13. The method of claim 6, comprisingadministering the vector comprising the nucleotide sequence encodingRPGR-ORF15 or a functional variant thereof at a dose of about 5×10⁶ toabout 5×10¹² vector genomes (vg) per eye.
 14. The method of claim 6,wherein the mammal is a human.
 15. The vector of claim 1, wherein therhodopsin kinase promoter comprises the nucleotide sequence of SEQ IDNO:
 10. 16. The vector of claim 1, wherein the vector comprises anucleotide sequence that is at least 90% identical to SEQ ID NO: 15 or26.
 17. An AAV vector comprising a nucleic acid comprising a nucleotidesequence encoding RPGR-ORF15 or a functional fragment or a functionalvariant thereof, wherein: (i) the vector further comprises a CMV/humanβ-globin intron, wherein the CMV/human β-globin intron comprises anucleotide sequence that is at least 90% identical to SEQ ID NO: 8,optionally wherein the vector further comprises a human β-globinpolyadenylation signal; and (ii) the nucleotide sequence encodingRPGR-ORF15 or a functional fragment or a functional variant thereof isoptionally under the transcriptional control of a rhodopsin kinasepromoter.
 18. The vector of claim 17, wherein the CMV/human β-globinintron comprises the nucleotide sequence of SEQ ID NO:
 8. 19. The vectorof claim 17, wherein the CMV/human β-globin intron comprises anucleotide sequence that is at least 95% identical to SEQ ID NO: 8.